Vinva Investment Management Ltd Sells 1,055 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vinva Investment Management Ltd cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,597 shares of the biopharmaceutical company’s stock after selling 1,055 shares during the quarter. Vinva Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,708,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Quent Capital LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares during the period. Cetera Investment Advisers lifted its holdings in shares of Regeneron Pharmaceuticals by 156.8% during the 1st quarter. Cetera Investment Advisers now owns 9,753 shares of the biopharmaceutical company’s stock valued at $9,387,000 after buying an additional 5,955 shares during the period. Cetera Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 114.1% during the 1st quarter. Cetera Advisors LLC now owns 5,218 shares of the biopharmaceutical company’s stock valued at $5,022,000 after buying an additional 2,781 shares during the period. Railway Pension Investments Ltd lifted its holdings in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Railway Pension Investments Ltd now owns 28,100 shares of the biopharmaceutical company’s stock valued at $27,046,000 after buying an additional 400 shares during the period. Finally, Hamilton Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 72.0% during the 1st quarter. Hamilton Wealth LLC now owns 461 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 193 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Piper Sandler decreased their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $754.87 on Friday. The company has a market cap of $82.95 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.91 and a beta of 0.15. The firm’s fifty day moving average is $913.54 and its 200 day moving average is $1,020.69. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.